Lyka Labs Limited (LYKALABS)

Price	113.05 2.55 (2.31%)	52 Week High	155.90
ISIN	INE933A01014	52 Week Low	88.50
Industry	Pharmaceuticals: Other	Volume	91,139
Sector	Health Technology	P/E Ratio TTM
Market Cap	3.7 B	1 Year Beta	0.96

Lyka Labs Limited (LYKALABS) is an Indian pharmaceutical company headquartered in Ahmedabad, Gujarat. It was founded in 1990 by Mr. Rajesh Shah. LYKALABS is a leading manufacturer of generic APIs (active pharmaceutical ingredients) and finished dosage forms. The company’s products are used in a wide range of therapeutic areas, including anti-infectives, anti-diabetics, and cardiovascular drugs. LYKALABS’s customers include a wide range of pharmaceutical companies in India and abroad.

LYKALABS has been profitable for over 32 years and has a strong balance sheet. The company is well-positioned to grow in the coming years, due to the increasing demand for generic APIs and finished dosage forms in India and abroad. However, there are also some risks associated with investing in LYKALABS, such as competition from other Indian and international pharmaceutical companies, regulation by the government of India and other countries, economic slowdown, and changing technologies.

Here are some of the key aspects of Lyka Labs Limited (LYKALABS):

Products and services: LYKALABS manufactures a range of generic APIs and finished dosage forms.
Customers: LYKALABS’s customers include a wide range of pharmaceutical companies in India and abroad.
Financial performance: LYKALABS has been profitable for over 32 years and has a strong balance sheet.
Market share: LYKALABS is a leading manufacturer of generic APIs and finished dosage forms in India.
Growth potential: LYKALABS is well-positioned to grow in the coming years, due to the increasing demand for generic APIs and finished dosage forms in India and abroad.

Here are some additional details about LYKALABS:

The company has a strong research and development (R&D) team that is constantly working to develop new products and technologies. This helps the company to stay ahead of the competition and meet the changing needs of its customers.
LYKALABS has a strong brand name and reputation for quality. This helps the company to attract customers and command a premium price for its products.
LYKALABS is committed to sustainability. The company has a number of initiatives in place to reduce its environmental impact, such as using water-saving technologies and renewable energy sources.

Overall, Lyka Labs Limited (LYKALABS) is a well-managed company with a strong track record of financial performance. The company is also a leading manufacturer of generic APIs and finished dosage forms in India with a bright future.

Here are some of the risks associated with investing in Lyka Labs Limited (LYKALABS):

Competition: LYKALABS faces competition from other Indian and international pharmaceutical companies.
Regulation: The pharmaceutical industry is regulated by the government of India and other countries. This regulation could impact LYKALABS’s business in the future.
Economic slowdown: If the Indian or global economy slows down, it could impact LYKALABS’s business.
Changing technologies: The pharmaceutical industry is constantly evolving with new technologies. LYKALABS needs to be able to adapt to these changes in order to remain competitive.

Ultimately, the decision of whether or not to invest in Lyka Labs Limited (LYKALABS) is a personal one. You should carefully consider your individual investment goals and risk tolerance before making a decision.

Lyka Labs Limited (LYKALABS) Chart

Technical Analysis of Lyka Labs Limited (LYKALABS)

Moving Averages

Period	Simple	Exponential
MA 5	112.00	112.06
MA 10	112.10	112.54
MA 20	114.54	113.27
MA 30	114.41	113.36
MA 50	112.86	112.84
MA 100	109.16	112.41
MA 200	115.18	115.28

Moving Average Rating

Technical Indicators

Name	Value	Name	Value
Aroon Up (14)	14.29	Aroon Down (14)	57.14
MACD Level (12, 26)	-0.62	MACD Signal (12, 26)	-0.20
Relative Strength Index (7)	51.24	Relative Strength Index (14)	49.19
Stochastic %D (14 3 3)	27.48	Stochastic %K (14 3 3)	29.65
Stochastic RSI Fast (3, 3, 14, 14)	22.70	Stochastic RSI Slow (3, 3, 14, 14)	18.46
Bollinger Upper Band (20)	120.39	Bollinger Lower Band (20)	108.68
Keltner Channels Upper Band (20)	121.56	Keltner Channels Lower Band (20)	104.99
Donchian Channels Upper Band (20)	124.00	Donchian Channels Lower Band (20)	108.40
Ichimoku Conversion Line (9, 26, 52, 26)	112.95	Ichimoku Base Line (9, 26, 52, 26)	116.20
Ichimoku Leading Span A (9, 26, 52, 26)	113.43	Ichimoku Leading Span B (9, 26, 52, 26)	115.05
Positive Directional Indicator (14)	14.42	Negative Directional Indicator (14)	16.05
Volume Weighted Average Price	111.93	Volume Weighted Moving Average 20	115.84

Oscillator Rating

Oscillators

Awesome Oscillator	-2.47
Ultimate Oscillator (7,14,28)	46.58
Money Flow (14)	27.92
Chaikin Money Flow (20)	-0.15
Commodity Channel Index (20)	-77.92
Bull Bear Power	-2.95

High / Low

1 Month	124.00	108.40
3 Month	124.00	106.00
6 Month	128.80	88.50
52 Week	155.90	88.50
All Time	267.00	8.15

Volume

Volume	91,139.00
Average 10 D	76,786.20
Average 30 D	103,674.67
Average 60 D	93,542.75
Average 90 D	181.7 T

Change/Volatility

Change	2.55 (2.31%)
Change 1W	-0.25 (-0.22%)
Change 1M	-3.15 (-2.71%)
Volatility	3.89
Volatility W	3.15

Performance

Yesterday	-14.23
Weekly	-0.26
Monthly	-2.54
3 Month	-4.19
6 Month	6.65
Yearly	-19.22
5 Year	189.87
All Time	451.46

Misc.

Average Day Range (14)	4.05
Average Directional Index (14)	23.47
Average True Range (14)	4.25
Williams Percent Range (14)	-56.94
Rate Of Change (9)	-0.09
Hull Moving Average (9)	111.45
Momentum (10)	-0.25
Parabolic SAR	118.25

PIVOT POINTS of Lyka Labs Limited (LYKALABS)

Name	S3	S2	S1	Pivot Points	R1	R2	R3
Classic	86.40	101.40	108.80	116.40	123.80	131.40	146.40
Fibonacci	101.40	107.13	110.67	116.40	122.13	125.67	131.40
Camarilla	112.08	113.45	114.83	116.40	117.58	118.95	120.33
Woodie's	94.60	101.80	109.60	116.80	124.60	131.80	139.60
DeMark's	-	-	112.60	118.30	127.60	-	-

Financial Analysis of Lyka Labs Limited (LYKALABS)

Income Statement

Basic EPS (FY)	-4.59
Basic EPS (TTM)	-5.31
EBITDA (Annual YoY Growth)	-83.61
EBITDA (Quarterly QoQ Growth)	-17.05
EBITDA (Quarterly YoY Growth)	-58.04
EBITDA (TTM)	130.7 M
EBITDA (TTM YoY Growth)	-83.05
EPS Diluted (Annual YoY Growth)	-133.77
EPS Diluted (FY)	-4.59
EPS Diluted (Quarterly QoQ Growth)	41.83
EPS Diluted (Quarterly YoY Growth)	-374.70
EPS Diluted (TTM)	-5.31
EPS Diluted (TTM YoY Growth)	-176.06
Free Cash Flow (Annual YoY Growth)	-116.76
Free Cash Flow Margin (FY)	-9.16
Gross Profit (Annual YoY Growth)	-84.43
Gross Profit (FY)	152.8 M
Gross Profit (MRQ)	39.7 M
Gross Profit (Quarterly QoQ Growth)	-29.29
Gross Profit (Quarterly YoY Growth)	-45.38
Gross Profit (TTM YoY Growth)	-75.95
Last Year Revenue (FY)	916.9 M
Revenue (Annual YoY Growth)	-52.36
Revenue per Employee (FY)	3.1 M
Revenue (Quarterly QoQ Growth)	2.87
Revenue (Quarterly YoY Growth)	-16.79
Revenue (TTM YoY Growth)	-48.61
Net Income (Annual YoY Growth)	-133.88
Net Income (FY)	-132,118,000.00
Net Income (Quarterly QoQ Growth)	38.59
Net Income (Quarterly YoY Growth)	-410.21
Net Income (TTM YoY Growth)	-178.10
Total Revenue (FY)	916.9 M

Valuation

Enterprise Value/EBITDA (TTM)	28.02
Number of Employees	296.00
Number of Shareholders	27,279.00
Shares Float	15 M
Price to Book (FY)	7.64
Price to Revenue Ratio (TTM)	4.14
Price to Sales (FY)	3.55
Total Shares Outstanding	33.1 M
Selling & Admin expenses Ratio (FY)	14.97
Selling & Admin expenses Ratio (TTM)	23.09

Balance Sheet

Total Assets (Annual YoY Growth)	-18.37
Total Debt (Annual YoY Growth)	-42.42
Total Liabilities (FY)	1.1 B
Cash & Equivalents (FY)	117.1 M
Cash and short term investments (FY)	117.2 M

Operating Metrics

Dividends

Margins

Net Margin (FY)	-14.41
Net Margin (TTM)	-17.70
Gross Margin (FY)	16.67
Gross Margin (TTM)	22.01
Operating Margin (FY)	1.76
Operating Margin (TTM)	-1.08
Pretax Margin (TTM)	-17.78

Related Companies (Peers) to Lyka Labs Limited (LYKALABS)

Price	635.95 2.00 (0.32%)	52 Week High	775.45
ISIN	INE098F01031	52 Week Low	554.05
Industry	Pharmaceuticals: Other	Volume	32,284
Sector	Health Technology	P/E Ratio TTM	43.12
Market Cap	18.5 B	1 Year Beta	0.88

Amrutanjan Health Care Limited (AMRUTANJAN) is an Indian pharmaceutical company headquartered in Hyderabad, India. It was incorporated in 1965. The company’s initial focus was on the manufacturing of pain relief balms. Amrutanjan has since expanded its operations to include a wide range of over-the-counter (OTC) products, including cough syrups, cold remedies, and skin care products. more about Amrutanjan Health Care Limited (AMRUTANJAN)

Price	866.40 -10.05 (-1.15%)	52 Week High	907.70
ISIN	INE406A01037	52 Week Low	397.20
Industry	Pharmaceuticals: Other	Volume	1.4 M
Sector	Health Technology	P/E Ratio TTM	25.67
Market Cap	513.3 B	1 Year Beta	0.66

Aurobindo Pharma Limited (AUROPHARMA) is an Indian multinational pharmaceutical company headquartered in Hyderabad, India. It was founded in 1986 by P. V. Ramana Rao. Aurobindo’s initial focus was on the manufacturing of generic pharmaceuticals. It has since expanded its operations to include a wide range of products, including APIs, finished dosages, and biosimilars. Aurobindo is more about Aurobindo Pharma Limited (AUROPHARMA)

Price	1,185.90 -20.50 (-1.70%)	52 Week High	1,277.90
ISIN	INE059A01026	52 Week Low	852.00
Industry	Pharmaceuticals: Other	Volume	2.8 M
Sector	Health Technology	P/E Ratio TTM	30.77
Market Cap	974.5 B	1 Year Beta	0.06

Cipla Limited (CIPLA) is an Indian multinational pharmaceutical company headquartered in Mumbai, India. It was founded in 1935 by Khwaja Abdul Hamied. CIPLA is one of the largest pharmaceutical companies in India and has a global presence, with operations in over 150 countries. The company’s products include generic drugs, branded drugs, and over-the-counter (OTC) products. more about Cipla Limited (CIPLA)

Price	336.80 13.60 (4.21%)	52 Week High	381.00
ISIN	INE101D01020	52 Week Low	267.75
Industry	Pharmaceuticals: Other	Volume	3.8 M
Sector	Health Technology	P/E Ratio TTM	18.89
Market Cap	78.2 B	1 Year Beta	0.79

Granules India Limited (GRANULES) is a well-established company with a strong track record in the Indian pharmaceutical industry. The company is a leading manufacturer of active pharmaceutical ingredients (APIs) and finished dosages in India. GRANULES has a strong customer base in the Indian and global pharmaceutical markets. GRANULES is well-positioned to capitalize on the growing more about Granules India Limited (GRANULES)

Price	1,097.45 -29.85 (-2.65%)	52 Week High	1,174.50
ISIN	INE326A01037	52 Week Low	628.00
Industry	Pharmaceuticals: Other	Volume	1.3 M
Sector	Health Technology	P/E Ratio TTM	51.59
Market Cap	513.9 B	1 Year Beta	0.46

Lupin Limited (LUPIN) is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. It was founded in 1968 by Mr. Desh Bandhu Gupta. LUPIN is one of the largest pharmaceutical companies in India, with a market capitalization of over $20 billion. The company manufactures a wide range of generic and branded pharmaceutical products, including anti-infectives, more about Lupin Limited (LUPIN)

Lyka Labs Limited (LYKALABS)

Lyka Labs Limited (LYKALABS) Chart